Advertisement
Screener

Alto Neuroscience, Inc. (ANRO) Total Long-Term Debt

2.8 / 5 stars · 68/120 Roast Me

Alto Neuroscience, Inc. Total Long-Term Debt

Alto Neuroscience, Inc. (ANRO) had Total Long-Term Debt of $10.25 million as of 2024-12-31, per its 10-K filed 2025-03-20.

Financial Statements › Balance Sheet › Liabilities › Long-Term Debt, Unclassified

us-gaap:LongTermDebt · last filed 2025-03-20

  • 2024-12-31: Long-term Debt $10.25M.
  • 2024-09-30: Long-term Debt $10.16M.
  • 2024-06-30: Long-term Debt $10.06M.
  • 2024-03-31: Long-term Debt $9.96M.
Period endLong-term Debt
2024-12-31$10.25M
10-K · filed 2025-03-20
2024-09-30$10.16M
10-Q · filed 2024-11-12
2024-06-30$10.06M
10-Q · filed 2024-08-13
2024-03-31$9.96M
10-Q · filed 2024-05-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
MANNKIND CORP (MNKD)United States$1.058B-30.41
Savara Inc (SVRA)United States$1.044B-9.10
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19